Microglia in Alzheimer's Disease Neurodegeneration

Microglia in Alzheimer's Disease Neurodegeneration

Pathway Diagram

Overview

Microglia are the primary innate immune cells of the central nervous system (CNS), representing approximately 10-15% of all brain cells. These resident macrophages originate from yolk sac progenitors during embryonic development and colonize the brain via hematopoietic pathways. In Alzheimer's disease (AD), microglia play a paradoxical role—simultaneously attempting to protect neural tissue through clearance of pathogenic proteins while contributing to neuroinflammation and neuronal death through excessive activation and release of neurotoxic factors. Understanding microglial dysfunction has become central to current theories of AD pathogenesis, as accumulating evidence suggests that impaired microglial responses to amyloid-beta (Aβ) and tau pathology may accelerate neurodegeneration.

Function/Biology

Microglia in Alzheimer's Disease Neurodegeneration

Pathway Diagram

Overview

Microglia are the primary innate immune cells of the central nervous system (CNS), representing approximately 10-15% of all brain cells. These resident macrophages originate from yolk sac progenitors during embryonic development and colonize the brain via hematopoietic pathways. In Alzheimer's disease (AD), microglia play a paradoxical role—simultaneously attempting to protect neural tissue through clearance of pathogenic proteins while contributing to neuroinflammation and neuronal death through excessive activation and release of neurotoxic factors. Understanding microglial dysfunction has become central to current theories of AD pathogenesis, as accumulating evidence suggests that impaired microglial responses to amyloid-beta (Aβ) and tau pathology may accelerate neurodegeneration.

Function/Biology

Microglia exist in dynamic functional states, ranging from resting/surveillance to activated/inflammatory phenotypes. In their resting state, microglia continuously survey the brain parenchyma using their highly ramified processes, monitoring for danger signals, pathogens, and dead cells. This surveillance function is mediated by pattern recognition receptors (PRRs) including toll-like receptors (TLRs), CD14, and CD11b. Upon encountering danger-associated molecular patterns (DAMPs) or pathogen-associated molecular patterns (PAMPs), microglia undergo rapid morphological changes—retracting processes and adopting an amoeboid configuration—while simultaneously releasing pro-inflammatory mediators.

Key microglial markers include IBA1 (ionized calcium-binding adapter molecule 1), which labels all microglial states, and CD11b (complement receptor 3), which intensifies during activation. Microglia regulate synaptic plasticity through complement system components including C1q and C3, which tag synapses for elimination through a process called synaptic pruning. Under physiological conditions, this pruning is essential for neural circuit refinement; however, excessive pruning contributes to cognitive decline in AD.

Role in Neurodegeneration

In Alzheimer's disease, microglial dysfunction represents a critical node in the pathological cascade. Microglia accumulate around amyloid plaques composed of aggregated Aβ42, particularly in the 5xFAD transgenic mouse model and human AD brain tissue. However, this accumulation often reflects a failed attempt at clearance rather than successful phagocytosis. Early-stage AD may involve impaired microglial response to Aβ, while chronic activation leads to sustained release of pro-inflammatory cytokines including tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6). These cytokines promote tau phosphorylation, increase blood-brain barrier permeability, and induce neuronal apoptosis.

Phosphorylated tau accumulation also activates microglia through receptor for advanced glycation end products (RAGE) and toll-like receptor 2 (TLR2), creating a feed-forward loop of neuroinflammation. Chronic microglial activation produces reactive oxygen species (ROS) and nitric oxide (NO), which oxidatively damage neuronal membranes and mitochondria, exacerbating energy depletion in vulnerable neurons.

Molecular Mechanisms

Microglial activation in AD involves several key signaling cascades. The CD33 gene, identified through genome-wide association studies (GWAS), encodes a myeloid inhibitory receptor that suppresses microglial phagocytosis of Aβ when bound to its ligand CD23L. Genetic variants in CD33 associated with AD risk correlate with reduced Aβ clearance. Additionally, the TREM2 (triggering receptor expressed on myeloid cells 2) pathway is critical for microglial response to Aβ and lipid ligands; TREM2 mutations increase AD risk through impaired immune regulation and altered microglial metabolism.

ApoE (apolipoprotein E), particularly the ε4 allele, modulates microglial lipid metabolism and inflammatory responses. APOE4-expressing microglia demonstrate reduced Aβ phagocytosis and enhanced pro-inflammatory cytokine production. The complement pathway, particularly C1q-mediated opsonization of Aβ and subsequent C3-mediated pruning, represents another critical mechanism linking microglial activation to synaptic loss.

Clinical/Research Significance

Therapeutic targeting of microglial dysfunction has emerged as a major strategy in AD drug development. Colony-stimulating factor 1 receptor (CSF1R) inhibitors can reduce microglial activation, showing promise in preclinical models of AD pathology. However, complete microglial elimination proves counterproductive, as some microglial functions—particularly Aβ clearance—are protective. Current research emphasizes promoting "protective" microglial phenotypes through enhancement of phagocytic capacity and reduction of neurotoxic mediator production.

PET imaging using microglial tracers like 11C-PK11195 demonstrates increased microglial activation in AD patients and preclinical stages, offering potential biomarkers for disease progression and therapeutic